IceCure Medical (ICCM) director Li Haixiang steps down from board

Rhea-AI Filing Summary

IceCure Medical Ltd. reported that Mr. Li Haixiang resigned from its Board of Directors, effective March 17, 2026. The company stated that his resignation was not related to any disagreement regarding its operations, policies, or practices. This report is also incorporated by reference into several existing IceCure Medical registration statements on Forms F-3 and S-8.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of March 2026 (Report No. 5)

Commission File Number: 001-40753

ICECURE MEDICAL Ltd.

(Translation of registrant’s name into English)

7 Ha’Eshel St., PO Box 3163

Caesarea, 3079504 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F      ☐ Form 40-F

CONTENTS

On March 17, 2026, IceCure Medical Ltd. (the “Company”) announced that Mr. Li Haixiang resigned as a member of the Board of Directors, effective March 17, 2026. Mr. Haixiang’s resignation was not related to any disagreement with the Company on any matter relating to its operations, policies or practices.

This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s Registration Statements on Form F-3 (File Nos. 333-290046, 333-267272 and 333-258660) and Form S-8 (File Nos. 333-270982, 333-264578, 333-262620 and 333-281587), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	IceCure Medical Ltd.
Date: March 17, 2026	By:	/s/ Eyal Shamir
		Eyal Shamir
		Chief Executive Officer

2

FAQ

What board change did IceCure Medical (ICCM) report in this 6-K?

IceCure Medical reported that director Mr. Li Haixiang resigned from its Board of Directors, effective March 17, 2026. The company noted that his resignation was not due to any disagreement regarding its operations, policies, or practices.

When did IceCure Medical (ICCM) director Li Haixiang’s resignation become effective?

Mr. Li Haixiang’s resignation from IceCure Medical’s Board of Directors became effective on March 17, 2026. This date is both the effective resignation date and the date referenced in the company’s Form 6-K report describing the board change.

Did IceCure Medical (ICCM) report any disagreement tied to Li Haixiang’s resignation?

IceCure Medical stated that Mr. Li Haixiang’s resignation was not related to any disagreement with the company on matters involving its operations, policies, or practices. This indicates the departure was described as amicable in the official disclosure.

Which SEC registration statements incorporate this IceCure Medical (ICCM) 6-K by reference?

This Form 6-K is incorporated by reference into IceCure Medical’s Form F-3 registration statements (File Nos. 333-290046, 333-267272, 333-258660) and Form S-8 registration statements (File Nos. 333-270982, 333-264578, 333-262620, 333-281587).

What is the purpose of IceCure Medical (ICCM) incorporating this 6-K into its F-3 and S-8 filings?

By incorporating this Form 6-K into its F-3 and S-8 registration statements, IceCure Medical makes the disclosed board change part of those filings from the submission date, unless later filings or reports supersede the information provided here.

Who signed IceCure Medical’s March 17, 2026 Form 6-K report?

The Form 6-K report was signed on behalf of IceCure Medical by Eyal Shamir, the company’s Chief Executive Officer. His electronic signature appears on the document dated March 17, 2026, confirming the company’s authorization of the filing.